neurogenic orthostatic hypotension (noh) is a debilitating condition associated with reduced quality of life, impairment in function and is also an independent predictor of mortality. [1] [2] [3] neurogenic orthostatic hypotension has a complex pathophysiology, variable presentation and broad differential diagnosis making it difficult to diagnose and manage. neurogenic orthostatic hypotension is defined clinically as a sustained fall in systolic blood pressure (SBp) ≥ 20 mmhg or diastolic blood pressure (dBp) ≥ 10 mmhg within three minutes (min) of standing from a supine or seated position. 4 alternatively, defining noh as a fall in postural SBp ≥ 30 mmhg may improve the false positive rate from 5% to 1%. 5 neurogenic orthostatic hypotension can be differentiated from other causes of orthostatic hypotension in that a lesion is present in the autonomic nervous system impeding sympathetic outflow, ultimately resulting in inadequate cerebral perfusion pressure.
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vasoconstriction and an elevation in heart rate in order to improve venous return and cardiac output. this mechanism is aided by the effect of the skeletal muscle pump, whereby isometric muscle contractions of the lower extremity musculature also improve venous return. in a simplified model of the pathophysiology of noh, patients with central and peripheral autonomic lesions have reduced or absent sympathetic responses to orthostatic stress resulting in reduced cerebral perfusion pressures, ultimately leading to noh symptoms (figure 1; for a full review of noh pathophysiology, see reference 9 ). neurogenic orthostatic hypotension is not a disease process in itself, but rather a consequence of other diseases. 6 it is classically associated with a group of neurodegenerative diseases characterized pathologically by the deposition of the protein ∝-synuclein in brain tissue, including parkinson's disease, multiple systems atrophy (MSa), pure autonomic failure (paf) and lewy body dementia. there are also a host of metabolic, autoimmune and neoplastic conditions that predispose to noh, most commonly diabetic autonomic neuropathy (table 1). 6 neurogenic orthostatic hypotension is also associated with aging, with increased prevalence in frail elderly and particularly, hospitalized patients. 6, 10, 11 Commonly prescribed medications increase the risk of orthostatic symptoms. Clinicians should be aware of the common classes of medications that cause or exacerbate noh, including alpha-blockers, anti-psychotics, antihypertensives and diuretics, antiparkinsonians, beta blockers, marijuana, phosphodiesterase inhibitors, tricyclic antidepressants and vasodilators. 12 identification of these medications and dosing adjustment/discontinuation where indicated is the first step in noh management (see below). Common medications shown to carry the highest risk of noh in elderly populations are hydrochlorthiazide, lisinopril, furosemide, trazodone and terazosin. 13 the risk of noh also increases with the absolute number of medications prescribed. 13 
Clinical presentation
patients with noh present with a wide constellation of both specific and generalized symptoms, making it difficult to recognize based on history alone. Cardinal features of noh such as lightheadedness, dizziness, pre-syncope and syncope upon standing are common, but may not be present.
14,15 non-specific complaints including weakness, fatigue, cognitive changes, blurred vision, tinnitus, "coat hanger" neck pain (in the suboccipital and paracervical regions), pallor, anxiety, palpitations and nausea have also been reported with less frequency. 14, 15 Cognitive dysfunction is the prevailing symptom in patients over 70-years-old. 15 the authors' experience is that non-specific fatigue/malaise may be the only presenting feature of noh. in cases where a diagnosis is elusive, bedside postural blood pressure (Bp) and heart rate measurements are simple to 16 temporality of symptoms should also be established, as noh tends to be most severe in the morning upon awakening secondary to nocturnal diuresis. that is secondary to the high prevalence of supine hypertension that is known to occur in patients with noh. 17 large meals also induce redistribution of blood flow to the digestive system causing postprandial (~30 minutes) worsening of symptoms.
18 querying patients about standing time until onset of orthostatic symptoms may also raise suspicion for noh, as the majority of patients report asymptomatic standing times of ~5 minutes (min) or less. 6 patients may also present with several other features of dysautonomia or with characteristics of motor dysfunction or peripheral neuropathy. 7 the history should include relevant questions about gastrointestinal, bladder, sexual and sudomotor dysfunction that increase the likelihood of a diagnosis of dysautonomia. it is important to remember that the extensive differential diagnosis for autonomic dysfunction necessitates a detailed neurological examination to look for features associated with particular disease processes. parkinsonian features, cognitive dysfunction, ataxia and signs of peripheral neuropathy or end organ damage may also be elicited.
history and physical examination should also be directed at ruling out potentially reversible and dangerous causes of orthostatic intolerance. Cardiac and endocrine abnormalities as well as intravascular volume depletion can mimic noh. however, these usually present as acute orthostatic intolerance, whereas noh secondary to autonomic dysfunction has a more insidious course. a detailed list of non-neurogenic causes of orthostatic hypotension is available elsewhere.
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Assessment
Measurement of orthostatic vitals at the bedside is a simple and easy screening method for noh. however their utility in ruling out a diagnosis is poor (Sensitivity 15.5%, Specificity 89.9% and positive predictive value 61.7%). 20 therefore, clinicians must maintain a high degree of suspicion for noh if symptoms are consistent with autonomic dysfunction, even in the absence of a significant orthostatic Bp drop at the bedside. prior to referral to the autonomic specialist for autonomic testing, a number of ancillary tests may be performed to rule out common mimics. these tests include screening for cardiac abnormalities (electrocardiogram, echocardiography, telemetry), measurement of intravascular volume status (serum complete blood count, electrolytes, blood urea nitrogen-to-creatinine ratio), screening for endocrine abnormalities (morning cortisol), peripheral neuropathy screen (vitamin B 12 , fasting plasma glucose) and brain imaging for structural abnormalities. 12 laboratory testing of autonomic function by the autonomic neurologist or cardiologist includes measures of sudomotor function, heart rate response to deep breathing, heart rate and Bp responses to Valsalva maneuver, heart rate and Bp responses to hut and thermoregulatory sweat testing. Cardiovascular response to hut is the current gold standard for diagnosis of noh, as it measures the sympathetic response to orthostatic stress (figure 2). Briefly, the patient is required to be resting supine in a quiet room for 15 min prior to hut, while beat-tobeat Bp and heart rate are recorded. the automated table is tilted slowly (~10 seconds (s)) until an upright angle of 70 degrees is reached. patients remain upright for five minutes, followed by a five minute supine measurement interval. a characteristic response to hut in a patient with pure autonomic failure is shown in figure 2 (SBp drop without concomitant heart rate increase). three common responses are seen on hut in patients with noh: 1) a sustained, slow drop in Bp (classical noh 21 3) maintenance of Bp for ~3 minutes followed by precipitous drop (i.e. delayed noh variant). 22 the three variants of noh are each associated with their own symptomatology. in classical noh, patients are likely to experience dizziness, fatigue, sensorial disturbances and occasionally syncope, between 30 s and 3 min of hut. patients will experience similar symptoms in the initial noh variant, however the onset will be immediately after hut. in the delayed noh variant, patients will experience prolonged prodromal symptoms including dizziness, fatigue, nausea, hyperhidrosis, sensorial disturbances, upper body muscle pain and frequently will experience syncopal events. 23 Management of neurogenic orthostatic hypotension a multifaceted approach to treatment of noh should include identification of potential hypotensive medications, patient education, non-pharmacologic management (a list of patient education strategies and non-pharmacologic treatments are listed in table 2 and an approach to pharmacotherapy is presented in figure 3 . Medications that can exacerbate orthostatic symptoms should be discontinued if possible. alternatively, dosing regimens for necessary medications can be altered (e.g. changing anti-hypertensives to nighttime dosing). a systematic review of the literature on non-pharmacologic and pharmacologic management of noh is available elsewhere.
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Patient education and non-pharmacologic management patient education is the initial component of the management strategy and significant time should be allotted for this at the time of diagnosis. frequent documentation of Bp as well as precipitating factors (e.g. large meals, alcohol, etc.) and the temporality of symptoms (e.g. post-prandial, early morning, etc.) in a diary will help patients identify risk factors so that behaviours can be modified. advising the patient to avoid large meals comprising a high proportion of carbohydrates, as well as alcohol can attenuate post-prandial symptoms. gradual and staged movement, such as moving from lying-to-sitting-tostanding over the course of 10-15 minutes, rather than moving immediately to standing can help reduce syncopal episodes upon awakening 17 and should be encouraged. avoiding Valsalva maneuvers (which increase intrathoracic pressure) during heavy lifting, straining or defecation can be useful in preventing symptoms during vulnerable activities. 17 nocturnal pressure diuresis attributed to supine hypertension in patients with noh, can lead to volume depletion and subsequently symptom exacerbation in the morning upon awakening. 17 this phenomenon can be mitigated by raising the head of the bed 10-20 degrees, which has been shown to reduce venous return and shift fluid to the extra-cellular space. 25 following patient education, the effectiveness of nonpharmacologic management is well established. 26 the modalities directly target the underlying pathophysiology of noh by reducing venous pooling and increasing plasma volume. they are well-tolerated and relatively safe compared to pharmacotherapy, which poses the risk of causing or exacerbating supine hypertension (see below). furthermore, non-pharmacologic management empowers patients to individually tailor their treatment regimens and gain a measure of control over their symptoms. there are a number of evidencebased non-pharmacologic modalities that should be prescribed to every patient with noh.
I. Countermaneuvers
actions such as isometric tensing of the quadriceps, gluteal and abdominal muscles, leg-crossing, squatting, knee flexing, toe raises and trunk bending can increase standing time 27 by increasing venous return and thus cardiac output and Bp in order to maintain cerebral perfusion pressure while standing.
28,29 these maneuvers can be used either during prolonged standing or to attenuate or arrest hypotensive symptoms at their onset.
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II. Increased salt and fluid intake
Maintenance of plasma volume is crucial in patients with inadequate vasoconstrictor mechanisms in order to avoid relative hypovolemia. 6, 30 increased dietary salt leads to increased extracellular fluid volume, including intravascular volume. the recommended daily salt intake for patients with noh is 10-20 g (180-360 mmol). 6 dietary increases can be achieved through liberal salt addition to meals or with 0.5 g and 1.0 g salt tablets in patients with intact renal function. however, it is our experience that the amount of salt in the north american diet continues to increase, making it easier to obtain target levels for sodium excretion (see below). increased dietary salt loading should be accompanied by increased fluid intake of 2.0-2.5 l/day. fluid in the form of sports drinks with electrolyte supplement has been anecdotally beneficial in our patients. the effect of salt and fluid loading can be monitored at home by the patient and during routine clinic visits. producing "clear, colourless urine" provides the patient with a visual target for maintaining adequate plasma volume.
26 a 24-hour urinary sodium excretion of 170 mmol or greater is the laboratory benchmark for the salt loading regimen and at least a total 24-hour urine output of 1.5 l is a reasonable surrogate to ensure appropriate plasma volume. 31 Beneficial effects can be experienced as early as three days after initiation of salt loading. if symptoms are not improved after one week, or with exacerbations of symptoms, a 24-hour urine collection for total urine volume and sodium excretion is indicated to determine if attempts at improving blood volume are adequate. 32 Close monitoring for signs of salt overload is also critical as patients with noh are susceptible to developing supine hypertension. 33 a 10 g daily dose of salt is double the amount recommended by the World health organization 34 and is associated with hypertension leading to unintended cardiovascular outcomes in the patient with noh. Should salt loading be accompanied by new or worsening supine hypertension, alternative treatment modalities are indicated.
increased fluid intake may also be used for expectant management of acute exacerbations of orthostatic intolerance. during periods of anticipated orthostatic stress (e.g. standing for prolonged periods, sitting in hot, humid weather), a useful strategy is to consume two 250 ml cups of cool water in rapid succession. this can increase SBp by up to 20 mmhg for up to two hours. 35, 36 this may also have the benefit of enhancing the pressor effect of vasocontrictor medications.
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III. Abdominal binders and compression stockings
tight-fitting abdominal binders, lower extremity compression stockings or compression shorts are useful to reduce venous pooling if they are put on prior to standing. 6 these garments have been shown to maintain Bp and increase *these indications are intended as general guidelines based on the authors' experience stroke volume in elderly subjects and patients with autonomic failure during hut. 38, 39 the abdomen is the most important site for these garments, as the majority of venous pooling occurs in the splanchnic venous system. 40 these garments may be cosmetically displeasing or cumbersome to patients, particularly in hot weather, but they can be used intermittently during periods of heightened orthostatic stress (e.g. during exercise). in the majority of cases, an abdominal binder is well-tolerated and can be worn under light clothing.
IV. Exercise
although not well-studied in autonomic failure, a combination of resistance and aerobic exercises may specifically target noh symptoms, as well as improve general health. exercise is particularly effective in combating noh symptoms that accompany deconditioning states such as bed rest. aerobic exercise has been shown to expand plasma volume, and resistance training of the abdominal and lower extremity musculature can improve the effectiveness of the skeletal muscle pump to reduce venous pooling. 26 ,41,42 a practical approach to initiating an exercise program must be provided to ensure compliance. it must also be considered that exercise can adversely exacerbate postural hypotension in patients with autonomic failure, as the sympathetic response to exercise is blunted. 43 other non-pharmacologic strategies, such as adequate hydration, avoiding food intake prior to exercise onset, countermaneuvers and compression garments previously mentioned, can attenuate exercise-induced hypotension. furthermore, exercising in a supine or sitting position (e.g. recumbent cycle ergometer) should be advised. further study is required to determine optimal exercise prescription and dose.
Pharmacotherapy
When non-pharmacologic management fails or orthostatic Bp control remains suboptimal, pharmacologic agents may be used. it must be emphasized that pharmacotherapy is usually ineffective, especially with progressive noh, if nonpharmacologic management is not used in combination. the central principle of pharmacologic management of noh is to achieve an appropriate increase in standing Bp through either a pressor effect or an increase in plasma volume, without causing or minimizing supine hypertension (≥ 180/110 mmhg). Clinicians should be aware of the high prevalence of supine hypertension that exists as part of the natural history of many dysautonomias 33 and practice slow medication titration with frequent monitoring so that a balance can be achieved between supine and standing Bp. the highest level of evidence exists for the sympathomimmetic Midodrine (amatine®, apomidodrine®), which has been subject to a double-blind, placebocontrolled trial. 44 other commonly used medications include pyridostigmine (Mestinon®, Mestinon Sr®) and fludrocortisone (florinef®). a summary of the practical recommendations on the use of common medications for noh are presented in table 3. adjuncts used for refractory noh or to target particular symptoms (e.g. octreotide for post-prandial noh) are also briefly discussed. a simple treatment algorithm including non-pharmacologic and pharmacologic treatment is presented in figure 3 .
Midodrine
Midodrine is the best studied of the noh medications. 44 ,45 a peripherally selective alpha-1-adrenoreceptor agonist, it acts as a vasopressor to increase venomotor and vasomotor tone, resulting in elevated standing SBp. optimal symptom control usually occurs at a dose of 10 mg orally, three times daily. 44 the initial dose is 2.5 mg, one to three times per day with dose increasing by 2.5 mg weekly until maximum daily dosing or optimal symptom control has been achieved. Midodrine requires slow titration and frequent Bp monitoring due to the high risk of supine hypertension. 16 accordingly, it is well established that Midodrine should not be taken in the evening (usually not after 6 pm). 5 Care should be taken in patients with baseline supine hypertension and other noh drugs should be considered. dosing regimens should also take into account that the duration of action is two to four hours with an onset of 0.5-1 hour. 5, 16 therefore, it can be taken prior to mealtime to mitigate postprandial exacerbation of noh. adverse effects other than supine hypertension include urinary retention, piloerection, pruritis, and gastrointestinal upset.
Pyridostigmine pyridostigmine has emerged as both an alternative and adjunct to midodrine. 5 pyridostigmine is an acetylcholinesterase inhibitor used predominantly in the treatment of myasthenia gravis. pyridostigmine presumably exerts its effect during standing when baroreceptors are unloaded and sympathetic ganglionic transmission, mediated through acetylcholine, is increased. By inhibiting the breakdown of acetylcholine in the synaptic cleft, pyridostigmine causes a mild increase in dBp during standing, while at the same time avoiding unwanted supine hypertension. 46, 47 pyridostigmine is indicated as frontline treatment on its own in those with mild orthostatic symptoms due to the modest increase in standing Bp. 6 it is started at 30 mg two or three times daily and increased to 60 mg three times daily. the combination of pyridostigmine with 2.5-5 mg once to twice daily doses of Midodrine has also been shown to improve orthostatic symptoms without causing supine hypertension. 47 Common side effects of pyridostigmine are cholinergic, including diaphoresis, hypersalivation, diarrhea and muscle cramping. 48 Fludrocortisone fludrocortisone is a synthetic mineralocorticoid, which acts as an aldosterone receptor agonist to increase plasma volume and improve blood vessel sensitivity to circulating catecholmines. 30, 49, 50 it is indicated in patients with moderate-tosevere symptoms who do not respond to Midodrine or in patients who do not tolerate dietary increases in salt and fluid. 6 treatment is initiated at a dose of 0.1 mg and can be increased to up to 0.3 mg per day in refractory patients. Side effects tend to occur much more frequently at higher doses. drug monitoring should include both Bp monitoring and weight measurement, as patients should expect to gain ~2-3 kg before symptoms resolve. regular electrolyte monitoring is also indicated due to the high risk of hypokalemia, and it is recommended that patients consume potassium-containing fruits and vegetables (e.g. bananas). 30 as with Midodrine, supine hypertension with higher doses is also a concern. 50 other side effects include peripheral edema, headache and occasionally congestive heart failure.
Adjuncts the role of adjunct medications in treatment of noh is to target specific pathophysiological processes in a subset of patients. these medications do not have the same body of evidence as those listed above and are not as well tolerated as frontline medications. they are usually considered only by an autonomic specialist.
Vasopressin analogues are considered to reduce nocturnal diuresis and subsequently prevent orthostatic symptoms upon awakening. they are usually reserved for patients with MSa, who have impaired hypothalamic release of vasopressin, or patients with nocturnal supine hypertension who are at higher risk for significant nocturnal intravascular volume loss. 16, 51 it is administered intranasally at a dose of 5-40 μg at bedtime. Side effects include water intoxication and hyponatremia, although these can usually be avoided at lower doses. 52 post-prandial hypotension is particularly problematic for patients with gastroparesis secondary to diabetic autonomic neuropathy. 53 When non-pharmacologic management fails (see above), there is some evidence that octreotide can be given subcutaneously (25-200 μg) with a meal to increase the rate of gastric emptying. 54 Because it is administered parenterally, it is usually reserved for refractory cases of post-prandial hypotension.
erythropoietin has the dual effect of increasing standing Bp and treating the normocytic, normochromic anemia that accompanies autonomic failure and diabetic autonomic neuropathy. 55, 56 it is administered three times per week, either subcutaneously or intravenously in 25-75 u/kg doses. again, care must be taken to monitor for supine hypertension. 55, 56 CONCLUSION this review provides a practical approach to the diagnosis, assessment and management of noh. Clinicians should be aware of the broad differential diagnosis, variable presentation and complex management of this common condition. the effectiveness and safety of non-pharmacologic management has been highlighted, along with potentially useful medications and their relative contraindications and side effects.
